The goal of this work was to determine whether deletion of ghrelin might prevent the age‐associated NAFLD and to determine whether its effects are mediated through the p300‐C/EBPα/β pathway. This evidence concerns the gene EP300 and metabolic dysfunction-associated steatotic liver disease.